JP2019510799A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510799A5 JP2019510799A5 JP2018552850A JP2018552850A JP2019510799A5 JP 2019510799 A5 JP2019510799 A5 JP 2019510799A5 JP 2018552850 A JP2018552850 A JP 2018552850A JP 2018552850 A JP2018552850 A JP 2018552850A JP 2019510799 A5 JP2019510799 A5 JP 2019510799A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- phenyl
- azetidine
- ethoxy
- fluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 97
- -1 1-Methylazetidine-3-yl Chemical group 0.000 claims description 52
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 10
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 claims description 8
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 4
- BXLHOSHUHPPGDV-UHFFFAOYSA-N 1h-azepin-2-ol Chemical compound OC1=CC=CC=CN1 BXLHOSHUHPPGDV-UHFFFAOYSA-N 0.000 claims 3
- DFVXEZWOASLALX-JOCHJYFZSA-N (1R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FC1=C(C(=CC(=C1)OCCN1CC(C1)CF)F)[C@@H]1N(CCC2=CC(=CC=C12)O)CC(F)(F)F DFVXEZWOASLALX-JOCHJYFZSA-N 0.000 claims 2
- VLOSTMAVKBAZEM-HSZRJFAPSA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-1-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@]1(N(CCC2=CC(=CC=C12)O)CC(F)(F)F)C VLOSTMAVKBAZEM-HSZRJFAPSA-N 0.000 claims 2
- DWFGIGKAFDWCKR-JOCHJYFZSA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline-6-carboxamide Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(CCC2=CC(=CC=C12)C(=O)N)CC(F)(F)F DWFGIGKAFDWCKR-JOCHJYFZSA-N 0.000 claims 2
- JWUOZESJFTULNI-AREMUKBSSA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methylpropyl)-1-methyl-3,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@]1(N(CCC2=CC(=CC=C12)O)CC(C)(C)F)C JWUOZESJFTULNI-AREMUKBSSA-N 0.000 claims 2
- ALHSDDHUURUUFF-XMMPIXPASA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methylpropyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FC(CN1[C@@H](C2=CC=C(C=C2CC1)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)(C)C ALHSDDHUURUUFF-XMMPIXPASA-N 0.000 claims 2
- GYPXHXYCRMGLOU-HSZRJFAPSA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3,3-dimethyl-2-(2,2,2-trifluoroethyl)-1,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(C(CC2=CC(=CC=C12)O)(C)C)CC(F)(F)F GYPXHXYCRMGLOU-HSZRJFAPSA-N 0.000 claims 2
- CLVNGZILSMJZDX-XMMPIXPASA-N (1R)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-1-methyl-3,4-dihydroisoquinolin-6-ol Chemical compound FC(CN1[C@](C2=CC=C(C=C2CC1)O)(C)C1=CC=C(C=C1)OCCN1CC(C1)CF)(CO)F CLVNGZILSMJZDX-XMMPIXPASA-N 0.000 claims 2
- BNQXMOBIGDCFOW-NFQMXDRXSA-N (1R)-2-(2-fluoro-2-methylpropyl)-1-methyl-1-[4-[2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy]phenyl]-3,4-dihydroisoquinolin-6-ol Chemical compound FC(CN1[C@@](C2=CC=C(C=C2CC1)O)(C1=CC=C(C=C1)OCCN1C[C@@H](CC1)C)C)(C)C BNQXMOBIGDCFOW-NFQMXDRXSA-N 0.000 claims 2
- BKBDCKCPOHJNMA-WAIKUNEKSA-N (1R,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N([C@@H](CC2=CC(=CC=C12)O)C)CC(F)(F)F BKBDCKCPOHJNMA-WAIKUNEKSA-N 0.000 claims 2
- KTLXJZWWYPXZBP-UZUQRXQVSA-N (1R,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N([C@@H](CC2=CC=CC=C12)C)CC(F)(F)F KTLXJZWWYPXZBP-UZUQRXQVSA-N 0.000 claims 2
- JMKZMWGLYQTHCM-MZNJEOGPSA-N (1R,3R)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FC(CN1[C@@H](C2=CC=C(C=C2C[C@H]1C)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)(CO)F JMKZMWGLYQTHCM-MZNJEOGPSA-N 0.000 claims 2
- PTNXVMQCPOSHGP-MZNJEOGPSA-N (1R,3R)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinolin-8-ol Chemical compound C[C@@H]1CC2=C([C@H](N1CC(F)(F)CO)C1=CC=C(OCCN3CC(CF)C3)C=C1)C(O)=CC=C2 PTNXVMQCPOSHGP-MZNJEOGPSA-N 0.000 claims 2
- KUSGGKASIHPZQJ-MZNJEOGPSA-N (1R,3R)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinoline-6-sulfonamide Chemical compound C[C@@H]1CC2=C(C=CC(=C2)S(N)(=O)=O)[C@H](N1CC(F)(F)CO)C1=CC=C(OCCN2CC(CF)C2)C=C1 KUSGGKASIHPZQJ-MZNJEOGPSA-N 0.000 claims 2
- DABPJEVISFOUNE-QMHKHESXSA-N (1R,4R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-4-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(C[C@@H](C2=CC(=CC=C12)O)C)S(=O)(=O)C DABPJEVISFOUNE-QMHKHESXSA-N 0.000 claims 2
- DABPJEVISFOUNE-WAIKUNEKSA-N (1R,4S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-4-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(C[C@H](C2=CC(=CC=C12)O)C)S(=O)(=O)C DABPJEVISFOUNE-WAIKUNEKSA-N 0.000 claims 2
- DFVXEZWOASLALX-QFIPXVFZSA-N (1S)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FC1=C(C(=CC(=C1)OCCN1CC(C1)CF)F)[C@H]1N(CCC2=CC(=CC=C12)O)CC(F)(F)F DFVXEZWOASLALX-QFIPXVFZSA-N 0.000 claims 2
- DWFGIGKAFDWCKR-QFIPXVFZSA-N (1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline-6-carboxamide Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(CCC2=CC(=CC=C12)C(=O)N)CC(F)(F)F DWFGIGKAFDWCKR-QFIPXVFZSA-N 0.000 claims 2
- JWUOZESJFTULNI-SANMLTNESA-N (1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methylpropyl)-1-methyl-3,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@]1(N(CCC2=CC(=CC=C12)O)CC(C)(C)F)C JWUOZESJFTULNI-SANMLTNESA-N 0.000 claims 2
- CLVNGZILSMJZDX-DEOSSOPVSA-N (1S)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-1-methyl-3,4-dihydroisoquinolin-6-ol Chemical compound FC(CN1[C@@](C2=CC=C(C=C2CC1)O)(C)C1=CC=C(C=C1)OCCN1CC(C1)CF)(CO)F CLVNGZILSMJZDX-DEOSSOPVSA-N 0.000 claims 2
- BNQXMOBIGDCFOW-HRFSGMKKSA-N (1S)-2-(2-fluoro-2-methylpropyl)-1-methyl-1-[4-[2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy]phenyl]-3,4-dihydroisoquinolin-6-ol Chemical compound FC(CN1[C@](C2=CC=C(C=C2CC1)O)(C1=CC=C(C=C1)OCCN1C[C@@H](CC1)C)C)(C)C BNQXMOBIGDCFOW-HRFSGMKKSA-N 0.000 claims 2
- UEMRZFLCPNBOQA-MWTRTKDXSA-N (1S,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N([C@@H](CC2=CC(=CC=C12)O)C)S(=O)(=O)C UEMRZFLCPNBOQA-MWTRTKDXSA-N 0.000 claims 2
- KTLXJZWWYPXZBP-SBUREZEXSA-N (1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N([C@H](CC2=CC=CC=C12)C)CC(F)(F)F KTLXJZWWYPXZBP-SBUREZEXSA-N 0.000 claims 2
- VOYGBWDJGBJHDH-HJPURHCSSA-N (1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline-6-carboxylic acid Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N([C@H](CC2=CC(=CC=C12)C(=O)O)C)CC(F)(F)F VOYGBWDJGBJHDH-HJPURHCSSA-N 0.000 claims 2
- UEMRZFLCPNBOQA-HJPURHCSSA-N (1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N([C@H](CC2=CC(=CC=C12)O)C)S(=O)(=O)C UEMRZFLCPNBOQA-HJPURHCSSA-N 0.000 claims 2
- JMKZMWGLYQTHCM-XDHUDOTRSA-N (1S,3S)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound C[C@H]1CC2=C(C=CC(O)=C2)[C@@H](N1CC(F)(F)CO)C1=CC=C(OCCN2CC(CF)C2)C=C1 JMKZMWGLYQTHCM-XDHUDOTRSA-N 0.000 claims 2
- PTNXVMQCPOSHGP-XDHUDOTRSA-N (1S,3S)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinolin-8-ol Chemical compound FC(CN1[C@H](C2=C(C=CC=C2C[C@@H]1C)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)(CO)F PTNXVMQCPOSHGP-XDHUDOTRSA-N 0.000 claims 2
- KUSGGKASIHPZQJ-XDHUDOTRSA-N (1S,3S)-2-(2,2-difluoro-3-hydroxypropyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-3,4-dihydro-1H-isoquinoline-6-sulfonamide Chemical compound FC(CN1[C@H](C2=CC=C(C=C2C[C@@H]1C)S(=O)(=O)N)C1=CC=C(C=C1)OCCN1CC(C1)CF)(CO)F KUSGGKASIHPZQJ-XDHUDOTRSA-N 0.000 claims 2
- DABPJEVISFOUNE-MWTRTKDXSA-N (1S,4S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-4-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(C[C@H](C2=CC(=CC=C12)O)C)S(=O)(=O)C DABPJEVISFOUNE-MWTRTKDXSA-N 0.000 claims 2
- AFHJGLYEFXWNLI-UHFFFAOYSA-N 1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-1-methyl-2-methylsulfonyl-3,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)C1(N(CCC2=CC(=CC=C12)O)S(=O)(=O)C)C AFHJGLYEFXWNLI-UHFFFAOYSA-N 0.000 claims 2
- DOKAKZWDBYSGJO-UYXZNNOOSA-N 2,2-difluoro-3-[(1R,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-[(1S)-1-hydroxyethyl]-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propan-1-ol Chemical compound FC(CO)(CN1[C@@H](C2=CC=C(C=C2C[C@H]1C)[C@H](C)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)F DOKAKZWDBYSGJO-UYXZNNOOSA-N 0.000 claims 2
- ZKQHQMPYZQYLCG-BVZFJXPGSA-N 2,2-difluoro-3-[(1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-(hydroxymethyl)-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propan-1-ol Chemical compound FC(CO)(CN1[C@H](C2=CC=C(C=C2C[C@@H]1C)CO)C1=CC=C(C=C1)OCCN1CC(C1)CF)F ZKQHQMPYZQYLCG-BVZFJXPGSA-N 0.000 claims 2
- DOKAKZWDBYSGJO-DGUDUIIESA-N 2,2-difluoro-3-[(1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-[(1S)-1-hydroxyethyl]-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propan-1-ol Chemical compound FC(CO)(CN1[C@H](C2=CC=C(C=C2C[C@@H]1C)[C@H](C)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)F DOKAKZWDBYSGJO-DGUDUIIESA-N 0.000 claims 2
- HAWGBQHBOGNATE-HSZRJFAPSA-N 2-fluoro-1-[(1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl]-2-methylpropan-1-one Chemical compound FC(C(=O)N1[C@@H](C2=CC=C(C=C2CC1)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)(C)C HAWGBQHBOGNATE-HSZRJFAPSA-N 0.000 claims 2
- HAWGBQHBOGNATE-QHCPKHFHSA-N 2-fluoro-1-[(1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl]-2-methylpropan-1-one Chemical compound CC(C)(F)C(=O)N1CCC2=C(C=CC(O)=C2)[C@@H]1C1=CC=C(OCCN2CC(CF)C2)C=C1 HAWGBQHBOGNATE-QHCPKHFHSA-N 0.000 claims 2
- XUNUAWWTPDXMAL-AREMUKBSSA-N 4-[(1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-yl]morpholine Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(CCC2=CC(=CC=C12)N1CCOCC1)CC(F)(F)F XUNUAWWTPDXMAL-AREMUKBSSA-N 0.000 claims 2
- XUNUAWWTPDXMAL-SANMLTNESA-N 4-[(1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-yl]morpholine Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(CCC2=CC(=CC=C12)N1CCOCC1)CC(F)(F)F XUNUAWWTPDXMAL-SANMLTNESA-N 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- LPSWHJANNYROHR-SANMLTNESA-N FC([C@]1(N(CCC2=CC(=CC=C12)O)CC(C)(C)F)C1=CC=C(C=C1)OCCN1CC(C1)CF)F Chemical compound FC([C@]1(N(CCC2=CC(=CC=C12)O)CC(C)(C)F)C1=CC=C(C=C1)OCCN1CC(C1)CF)F LPSWHJANNYROHR-SANMLTNESA-N 0.000 claims 2
- IWCNMGHVEYTYJN-YHAMSUFESA-N FC1=C(C(=CC(=C1)OCCN1CC(C1)CF)F)[C@@H]1N([C@H](CC2=C3C(=CC=C12)NN=C3)C)CC(C)(C)F Chemical compound FC1=C(C(=CC(=C1)OCCN1CC(C1)CF)F)[C@@H]1N([C@H](CC2=C3C(=CC=C12)NN=C3)C)CC(C)(C)F IWCNMGHVEYTYJN-YHAMSUFESA-N 0.000 claims 2
- GYPXHXYCRMGLOU-QHCPKHFHSA-N FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(C(CC2=CC(=CC=C12)O)(C)C)CC(F)(F)F Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(C(CC2=CC(=CC=C12)O)(C)C)CC(F)(F)F GYPXHXYCRMGLOU-QHCPKHFHSA-N 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- BSUFGZPLIVGYCD-UHFFFAOYSA-N OC1=CC2=C(C=C1)C(N(CC2)C1=CC=CC=C1)C1=CC=C(OC2CN(CCCF)C2)C=C1 Chemical compound OC1=CC2=C(C=C1)C(N(CC2)C1=CC=CC=C1)C1=CC=C(OC2CN(CCCF)C2)C=C1 BSUFGZPLIVGYCD-UHFFFAOYSA-N 0.000 claims 2
- APHXUUHZAZJKAK-QHCPKHFHSA-N [(1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-yl]methanol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(CCC2=CC(=CC=C12)CO)CC(F)(F)F APHXUUHZAZJKAK-QHCPKHFHSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LPSWHJANNYROHR-AREMUKBSSA-N (1R)-1-(difluoromethyl)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methylpropyl)-3,4-dihydroisoquinolin-6-ol Chemical compound FC([C@@]1(N(CCC2=CC(=CC=C12)O)CC(C)(C)F)C1=CC=C(C=C1)OCCN1CC(C1)CF)F LPSWHJANNYROHR-AREMUKBSSA-N 0.000 claims 1
- YJLADFAOINOYCZ-JOCHJYFZSA-N (1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(CCC2=CC(=CC=C12)O)S(=O)(=O)C YJLADFAOINOYCZ-JOCHJYFZSA-N 0.000 claims 1
- UEMRZFLCPNBOQA-WAIKUNEKSA-N (1R,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N([C@@H](CC2=CC(=CC=C12)O)C)S(=O)(=O)C UEMRZFLCPNBOQA-WAIKUNEKSA-N 0.000 claims 1
- UEMRZFLCPNBOQA-QMHKHESXSA-N (1R,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N([C@H](CC2=CC(=CC=C12)O)C)S(=O)(=O)C UEMRZFLCPNBOQA-QMHKHESXSA-N 0.000 claims 1
- VLOSTMAVKBAZEM-QHCPKHFHSA-N (1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-1-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@]1(N(CCC2=CC(=CC=C12)O)CC(F)(F)F)C VLOSTMAVKBAZEM-QHCPKHFHSA-N 0.000 claims 1
- ALHSDDHUURUUFF-DEOSSOPVSA-N (1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methylpropyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FC(CN1[C@H](C2=CC=C(C=C2CC1)O)C1=CC=C(C=C1)OCCN1CC(C1)CF)(C)C ALHSDDHUURUUFF-DEOSSOPVSA-N 0.000 claims 1
- YJLADFAOINOYCZ-QFIPXVFZSA-N (1S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(CCC2=CC(=CC=C12)O)S(=O)(=O)C YJLADFAOINOYCZ-QFIPXVFZSA-N 0.000 claims 1
- BKBDCKCPOHJNMA-HJPURHCSSA-N (1S,3S)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N([C@H](CC2=CC(=CC=C12)O)C)CC(F)(F)F BKBDCKCPOHJNMA-HJPURHCSSA-N 0.000 claims 1
- DABPJEVISFOUNE-HJPURHCSSA-N (1S,4R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-4-methyl-2-methylsulfonyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@@H]1N(C[C@@H](C2=CC(=CC=C12)O)C)S(=O)(=O)C DABPJEVISFOUNE-HJPURHCSSA-N 0.000 claims 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 claims 1
- ZKQHQMPYZQYLCG-IQGLISFBSA-N 2,2-difluoro-3-[(1R,3R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-6-(hydroxymethyl)-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propan-1-ol Chemical compound FC(CO)(CN1[C@@H](C2=CC=C(C=C2C[C@H]1C)CO)C1=CC=C(C=C1)OCCN1CC(C1)CF)F ZKQHQMPYZQYLCG-IQGLISFBSA-N 0.000 claims 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 claims 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 claims 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 claims 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 claims 1
- RSGWJAIJNYLBMJ-UHFFFAOYSA-N 6-[2,6-difluoro-4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-3,7-bis(2-fluoro-2-methylpropyl)-8-methyl-8,9-dihydro-6H-pyrazolo[4,3-f]isoquinoline Chemical compound CC1CC2=C(C=CC3=C2C=NN3CC(C)(C)F)C(N1CC(C)(C)F)C1=C(F)C=C(OCCN2CC(CF)C2)C=C1F RSGWJAIJNYLBMJ-UHFFFAOYSA-N 0.000 claims 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 claims 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 claims 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 claims 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 claims 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 claims 1
- QFDWEGJPSMCKDG-UHFFFAOYSA-N OC1=CC2=C(C=C1)C(N(CC2)C1=CC=CC=C1)C1=CC=C(OCCN2CC(CF)C2)C=C1 Chemical compound OC1=CC2=C(C=C1)C(N(CC2)C1=CC=CC=C1)C1=CC=C(OCCN2CC(CF)C2)C=C1 QFDWEGJPSMCKDG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- APHXUUHZAZJKAK-HSZRJFAPSA-N [(1R)-1-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinolin-6-yl]methanol Chemical compound FCC1CN(C1)CCOC1=CC=C(C=C1)[C@H]1N(CCC2=CC(=CC=C12)CO)CC(F)(F)F APHXUUHZAZJKAK-HSZRJFAPSA-N 0.000 claims 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 *C(*CCOC(*)=**=C(C1N(*)CCc2ccccc12)*=I)(**=I)I Chemical compound *C(*CCOC(*)=**=C(C1N(*)CCc2ccccc12)*=I)(**=I)I 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/078807 | 2016-04-08 | ||
| CNPCT/CN2016/078807 | 2016-04-08 | ||
| PCT/EP2017/058313 WO2017174757A1 (en) | 2016-04-08 | 2017-04-07 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510799A JP2019510799A (ja) | 2019-04-18 |
| JP2019510799A5 true JP2019510799A5 (https=) | 2021-08-12 |
| JP7241542B2 JP7241542B2 (ja) | 2023-03-17 |
Family
ID=58489690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552850A Active JP7241542B2 (ja) | 2016-04-08 | 2017-04-07 | テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9969732B2 (https=) |
| EP (1) | EP3440067B1 (https=) |
| JP (1) | JP7241542B2 (https=) |
| CN (1) | CN109219604B (https=) |
| WO (1) | WO2017174757A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| EP3640251B1 (en) * | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| EA037533B9 (ru) * | 2016-12-16 | 2021-05-27 | Астразенека Аб | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА |
| PL3494116T3 (pl) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| NZ764463A (en) * | 2017-11-14 | 2023-07-28 | Kind Pharmaceutical | Heterocyclic compound and application thereof in medicine |
| EP3709997A1 (en) * | 2017-11-16 | 2020-09-23 | Novartis AG | Pharmaceutical combination comprising lsz102 and ribociclib |
| CN112424205B (zh) * | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
| CN111499614A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN114746424B (zh) * | 2020-01-10 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN115667275B (zh) * | 2020-04-21 | 2024-02-23 | 南京再明医药有限公司 | 含硼化合物及其应用 |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| MX2022013391A (es) | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| CN111825613B (zh) * | 2020-08-17 | 2022-02-15 | 上海勋和医药科技有限公司 | 作为选择性雌激素受体下调剂的四氢异喹啉类化合物、合成方法及用途 |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| CN116669729A (zh) * | 2021-02-08 | 2023-08-29 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| EP4294398A4 (en) * | 2021-02-19 | 2025-03-26 | The University of Chicago | Estrogen receptor alpha antagonists and their uses |
| CN113024460B (zh) * | 2021-03-10 | 2022-11-08 | 中国药科大学 | 作为雌激素受体与组蛋白去乙酰化酶双靶点化合物的四氢异喹啉类化合物、合成方法及用途 |
| WO2022194096A1 (zh) * | 2021-03-15 | 2022-09-22 | 深圳福沃药业有限公司 | 雌激素受体调节剂 |
| AU2022307207A1 (en) * | 2021-07-09 | 2024-02-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Salt types of tricyclic tetrahydro isoquinoline derivative |
| TW202317539A (zh) * | 2021-07-15 | 2023-05-01 | 大陸商四川海思科製藥有限公司 | 芳氨基衍生物雌激素受體調節劑及其用途 |
| WO2024042185A1 (en) * | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted tetrahydroisoquinoline-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof. |
| CN115252606B (zh) * | 2022-09-29 | 2023-02-03 | 北京市神经外科研究所 | 化合物在制备用于治疗肿瘤的药物中的应用 |
| TW202547495A (zh) * | 2024-04-01 | 2025-12-16 | 大陸商山東盛迪醫藥有限公司 | 一種選擇性雌激素受體降解劑的製備方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5981521A (en) * | 1998-11-13 | 1999-11-09 | Abbott Laboratories | Tetrahydroisoquinoline derivatives as LHRH antagonists |
| AU766648B2 (en) * | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| ATE310728T1 (de) * | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| WO2002046164A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic compounds |
| CA2819299A1 (en) * | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| CN102875466A (zh) * | 2012-04-23 | 2013-01-16 | 中国药科大学 | 异喹啉酮衍生物,其制备方法及其医药用途 |
| WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| WO2017182493A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| EP3640251B1 (en) * | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
-
2017
- 2017-04-07 EP EP17715939.9A patent/EP3440067B1/en active Active
- 2017-04-07 WO PCT/EP2017/058313 patent/WO2017174757A1/en not_active Ceased
- 2017-04-07 CN CN201780034424.1A patent/CN109219604B/zh active Active
- 2017-04-07 US US15/481,757 patent/US9969732B2/en active Active
- 2017-04-07 JP JP2018552850A patent/JP7241542B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510799A5 (https=) | ||
| JP7270630B2 (ja) | 抗癌剤として有用なテトラヒドロキナゾリン誘導体 | |
| JP4662823B2 (ja) | タンパク質キナーゼの阻害剤としての置換ピリミジンおよびピリミジン誘導体を調製する方法 | |
| JP3834663B2 (ja) | イソキノリン誘導体及び医薬 | |
| NL1026827C2 (nl) | Derivaten van piperazine. | |
| TWI660946B (zh) | 作為ｍａｇｌ抑制劑之胺基甲酸１，１，１－三氟－３－羥基丙烷－２－酯衍生物 | |
| TW202140461A (zh) | Ras抑制劑及其使用方法 | |
| JP2012528178A5 (https=) | ||
| JP2001521926A (ja) | 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換 | |
| HRP960576A2 (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives | |
| UA73932C2 (uk) | Похідні хіназоліну як інгібітори ангіогенезу | |
| JP2016527263A (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
| EA009941B1 (ru) | Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления | |
| MX2011000352A (es) | Derivados de triazol utiles para el tratamiento de enfermedades. | |
| US20050043300A1 (en) | Piperazine derivatives | |
| RU2013104038A (ru) | СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2008546751A (ja) | 医薬組成物 | |
| JP2022554392A5 (https=) | ||
| JP2017057221A (ja) | 治療活性組成物およびそれらの使用方法 | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| JP2013538811A (ja) | キナゾリン化合物及びその使用方法 | |
| AU2017359773A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| WO2005121094A1 (en) | Piperazine and piperidine derivatives as anti-hiv-agents | |
| NL1028193C2 (nl) | Farmaceutisch werkzame verbindingen. | |
| EP4493182A1 (en) | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor |